Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q2FY23 Quarterly Result Announced for Dr. Lal Pathlabs Ltd.

 Dr Lal Pathlabs announced Q2FY23 results: Consolidated Q2FY23 vs Q2FY22: Non-Covid Revenue increased by 14.8% in Q2FY23 to Rs 514 crore vs Rs 448 crore in Q2FY22 Total revenue increased by 7.1% in Q2FY23 to Rs 534 crore vs Rs 498 crore in Q2FY22 Covid and allied contributed 3.7% to revenue in Q2FY23; 10.1% in Q2FY22 Normalised EBITDA (after adjustment for stock-based compensation, CSR) for Q2FY23 is at Rs 150 crore (margins 28.1%) vs Rs 152 crore in the same quarter last year Normalised PBT at Rs 117 crore, margins 21.9% vs Rs 131 crore in Q2 last year Normalised PAT at Rs 86 crore, margins 16.1% vs Rs 96 crore in Q2 last year Result PDF
08-11-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed herewith the Press Release for the unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022.
08-11-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find attached a copy of Company''s Q2 & H1 FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022, approved by the Board of Directors in their meeting held on November 08, 2022.
08-11-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Please take note that the Board of Directors in their meeting held today i.e. November 08, 2022 approved the appointment of Mr. Rohit Bhasin (DIN: 02478962) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from November 08, 2022 subject to approval of Shareholders of the Company through postal ballot process. Please also take note that Mr. Rohit Bhasin is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.
08-11-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Board Meeting Outcome for Outcome Of The Board Meeting Held On November 11, 2022

 Please take note that the Board of Directors in their meeting held today i.e. November 08, 2022 approved the following item(s): 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2022. A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Half Year ended September 30, 2022 are attached herewith as an Annexure- A. 2. Appointment of Mr. Rohit Bhasin (DIN: 02478962) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from November 08, 2022 subject to approval of Shareholders of the Company through postal ballot process. Please also take note that Mr. Rohit Bhasin is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.
08-11-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Results:Un-Audited Financial Results For Quarter And Half Year Ended September 30, 2022

 Please take note that the Board of Directors in their meeting held today i.e. November 08, 2022 approved the following item(s): 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2022. A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Half Year ended September 30, 2022 are attached herewith as an Annexure- A. 2. Appointment of Mr. Rohit Bhasin (DIN: 02478962) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from November 08, 2022 subject to approval of Shareholders of the Company through postal ballot process. Please also take note that Mr. Rohit Bhasin is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.
08-11-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Tuesday, November 08, 2022 at 4:30 pm IST to discuss the financial and operating performance for Q2 & H1 FY23. We request you to kindly take the same on record.
01-11-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Board Meeting Intimation for Notice Of Board Meeting

 Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2022 ,inter alia, to consider and approve the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2022.
01-11-2022

Diagnostics is the next battleground: How Dr Lal Pathlabs, SRL are trying to hold fort

 The diagnostics majors are looking at inorganic growth for their network expansion which is further heightening the competition. For instance, Dr Lal PathLabs acquired Suburban Diagnostics in 2021 for Rs 925 crore in West India. It is also planning expansion in South India.
24-10-2022
Bigul

Dr. Lal PathLabs Ltd - 539524 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a copy of the Certificate received from Link Intime India Private Limited, the RTA (Registrars & Share Transfer Agent) of the Company viz. Dr. Lal PathLabs Limited, confirming the compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2022.
12-10-2022
Next Page
Close

Let's Open Free Demat Account